MoonLake Immunotherapeutics MLTX Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -77.7%-17.2pp | -60.5%-6.3pp | -54.2%-13.9pp | -40.3%-9.7pp | -30.6%-5.3pp | |
| Return on assets | -56.4%-6.0pp | -50.4%-5.2pp | -45.1%-10.1pp | -35.1%-8.1pp | -27%-3.3pp | |
| Return on invested capital | -199.6%-44.1pp | -155.5%+198pp | -353.1%-221pp | -132.2%-18.1pp | -114.1%-23.9pp | |
| Liquidity | ||||||
| Current ratio | 8.6×-0.7× | 9.3×+0.8× | 8.5×-8.1× | 16.6×-4.5× | 21.1×0.0× | |
| Quick ratio | 8.6×-0.7× | 9.3×+0.8× | 8.5×-8.1× | 16.6×-4.5× | 21.1×0.0× | |
| Cash ratio | 6.5×-0.9× | 7.4×+0.1× | 7.3×-4.0× | 11.2×-0.1× | 11.3×+3.3× | |
| Leverage | ||||||
| Debt-to-equity | 0.4×+0.1× | 0.2×0.0× | 0.3×0.0× | 0.2×0.0× | 0.2×+0.2× | |
| Debt-to-assets | 0.3×+0.1× | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | 0.1×+0.1× | |
| Interest coverage | -28.2×+5.6× | -33.8×+9.8× | -43.6×+54.1× | -97.7×+9,389× | -9,486.4×— | |
| Per Share | ||||||
| Book value per share | $3.56-24.5% | $4.72+3.6% | $4.56-18.4% | $5.59-13.3% | $6.44-9.3% | |
| Valuation | ||||||
| Market capitalization | $1.34B+43.2% | $933.77M+105% | $455.31M-84.3% | $2.9B+17.5% | $2.47B-27.6% | |
| Enterprise value | $1.14B+68.8% | $674.96M+274% | $180.33M-93.3% | $2.67B+17.4% | $2.28B-29.7% | |
| Price / book | 5.3×+2.2× | 3.1×+1.5× | 1.6×-6.6× | 8.2×+2.1× | 6.1×-1.6× | |
| Free cash flow yield | -16.8%+4.2pp | -21%+19.8pp | -40.8%-35.1pp | -5.7%-0.1pp | -5.7%-2.2pp | |
| Earnings yield | -19.2%+5.1pp | -24.3%+21.9pp | -46.2%-40.2pp | -6.1%-0.2pp | -5.9%-2.4pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do MoonLake Immunotherapeutics's ratios come from?
- Every ratio is computed from MoonLake Immunotherapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.